TRICARE Trap: Weight Loss Shot Vanishes

For veterans and military families, the same GLP-1 shot can be fully covered for diabetes but effectively out of reach for simple weight loss, depending on your diagnosis and plan.

Story Snapshot

Ozempic and Mounjaro are covered by VA and TRICARE mainly for type 2 diabetes, not general weight loss.
Wegovy and Zepbound can be covered for weight management under some TRICARE plans but are tightly restricted or excluded under VA and CHAMPVA.
TRICARE Prime and Select keep access to GLP-1 weight-loss drugs, while TRICARE For Life and other groups lose it after August 31, 2025.
VA and CHAMPVA tie coverage to narrow diagnoses like heart disease risk or sleep apnea, leaving many struggling with obesity without help.

What These Drugs Do — And Why The Label Matters

Ozempic, Wegovy, Mounjaro, and Zepbound are all GLP-1 medications, but the Food and Drug Administration approved each for different main uses. Wegovy and Zepbound are approved for chronic weight management, while Ozempic and Mounjaro are approved for type 2 diabetes, with some added heart or kidney benefits. That split matters because federal plans often follow the label. If a doctor prescribes Ozempic only for weight loss, the plan can call it “off-label” and deny coverage.

For many readers, this feels like classic bureaucratic games. People see one shot helping their neighbor lose 40 pounds and fix blood sugar, but the government plan still says “no” because the wrong diagnosis code is in the chart. This fuels anger on the right and the left. Both sides see a system more focused on rules, costs, and self-protection than on helping veterans, retirees, and families reach basic health goals.

TRICARE: Diabetes Easier, Weight Loss Depends On Your Plan

TRICARE’s own pharmacy guidance says it covers certain GLP-1 medications like Ozempic and Mounjaro for type 2 diabetes when you have prior authorization. That means your doctor must show you have diabetes and meet plan criteria, but coverage is possible. For weight loss, TRICARE does cover Wegovy and Zepbound for chronic weight management, yet only if you are in TRICARE Prime, TRICARE Select, or certain related plans and meet clinical rules.

TRICARE’s contractor Express Scripts explains that Wegovy, Zepbound, and other weight-loss drugs are covered for Prime and Select beneficiaries with approved prior authorization. Starting August 31, 2025, TRICARE will end coverage of weight-loss medications for people not on Prime or Select, including many TRICARE For Life users. Military news outlets warn that retirees on TRICARE For Life will lose access to Wegovy and Zepbound for weight loss after that date. This turn hits older veterans hard, including many who already feel forgotten by the system.

VA And CHAMPVA: Diagnosis-Driven Rules That Shut Out Obesity Alone

The Department of Veterans Affairs takes an even tougher stance. One detailed review of VA formulary rules says the VA covers Ozempic for type 2 diabetes only, not for weight loss, and that Wegovy, Mounjaro, and Zepbound are not on the VA National Formulary at all as of April 2026. The same source says VA criteria require a type 2 diabetes diagnosis with poor blood sugar control and high heart risk. Simple obesity, even with a high body mass index, does not qualify.

Official VA information for family members under CHAMPVA confirms this diagnosis-first approach. CHAMPVA covers Ozempic and Mounjaro only for type 2 diabetes, Zepbound only for obstructive sleep apnea, and Wegovy only for a specific heart risk condition called prevention of major adverse cardiovascular events. The VA states clearly that CHAMPVA does not cover GLP-1 medications prescribed for weight loss. In plain terms, if your doctor writes “obesity” as the main problem, CHAMPVA will not pay, even if the same drug would be covered for diabetes or sleep apnea.

Why This Feels Rigged — And How To Work The System

These rules feed a common belief that the “deep state” takes care of budgets and drug companies first and patients last. Veterans hear that the VA negotiates low prices and that GLP-1s can prevent heart attacks and treat liver disease, yet they are told obesity alone is not a valid reason. TRICARE families see coverage change by plan name and date, not by need. Many on both sides of the political aisle see this as one more sign the federal health system is broken.

Still, there are narrow paths. For TRICARE users, being on Prime or Select and working with a network doctor who can document diabetes, sleep apnea, or heart risk gives the best shot at coverage for these drugs. For VA care, veterans who have type 2 diabetes or specific heart or liver diagnoses stand a better chance of getting Ozempic or Wegovy approved when their doctors show medical necessity and, in some cases, participation in programs like MOVE! weight management. The key takeaway: the diagnosis code often matters more than the scale number.